

Cannabis-based products for medicinal use

Consultation on draft scope – deadline for comments is 5pm on Tuesday 4 December 2018

email: CannabisMedUse@nice.org.uk

| | |
|---|--|
| | <p>Please read the checklist for submitting comments at the end of this form. We cannot accept forms that are not filled in correctly or arrive after the deadline.</p> <p>In addition to your comments below, we would like to hear your views on these questions:</p> <ol style="list-style-type: none"> 1. Are there any cost saving interventions or examples of innovative approaches that should be considered for inclusion in this guideline? <p>Developing NICE guidance: how to get involved has a list of possible areas for comment on the draft scope.</p> |
| <p>Organisation name – Stakeholder or respondent (if you are responding as an individual rather than a registered stakeholder please leave blank):</p> | <p>General Medical Council</p> |
| <p>Disclosure Please disclose any past or current, direct or indirect links to, or funding from, the tobacco industry.</p> | <p><u>None</u></p> |
| <p>Name of person completing form:</p> | |

| Type | | [for office use only] | |
|-------------|---|---|--|
| Comment No. | Page number or ' general ' for comments on the whole document | Line number or ' general ' for comments on the whole document | Comments Insert each comment in a new row. Do not paste other tables into this table, as your comments could get lost – type directly into this table. |
| 1 | General | General | We are pleased that NICE is developing guidance on prescribing of cannabis-based products for medicinal use. In particular we welcome that the guideline will be in line with our guidance on prescribing unlicensed medicines in Good practice in prescribing and managing medicines and devices . |
| 2 | General | General | We believe the draft scope should be clear that, as per the legislation, cannabis-based products for medicinal use (where they are a special medicinal product) are restricted to <i>use in accordance with a prescription or direction of a specialist medical practitioner</i> . |
| 3 | 5 | 6 | We welcome the signposting to our guidance, however, we believe the link should be corrected to “GMC’s guidance”. |
| 4 | 5 | 7 | We are pleased that the draft scope of the guideline references GMC guidance on prescribing unlicensed medicines. It is important to acknowledge that doctors may prescribe an unlicensed medicine where they conclude, for medical reasons, that it is necessary to do so to meet the specific needs of the patient. Reasons that may account for this include when other treatments haven’t helped or have been discounted. |

Please add extra rows as needed

Please return to: CannabisMedUse@nice.org.uk

NICE reserves the right to summarise and edit comments received during consultations, or not to publish them at all, where in the reasonable opinion of NICE, the comments are voluminous, publication would be unlawful or publication would be otherwise inappropriate.

Checklist for submitting comments

- Use this form and submit it as a Word document (not a PDF).
- Complete the disclosure about links with, or funding from, the tobacco industry.
- Include page and line number (not section number) of the text each comment is about.
- Combine all comments from your organisation into 1 response. We cannot accept more than 1 response from each organisation.
- Do not paste other tables into this table – type directly into the table.
- Underline and highlight any confidential information or other material that you do not wish to be made public.
- Do not include medical information about yourself or another person from which you or the person could be identified.
- Spell out any abbreviations you use
- For copyright reasons, do not include attachments such as research articles, letters or leaflets. We return comments forms that have attachments without reading them. The stakeholder may resubmit the form without attachments.

Note: We reserve the right to summarise and edit comments received during consultations, or not to publish them at all, if we consider the comments are too long, or publication would be unlawful or otherwise inappropriate.

Comments received during our consultations are published in the interests of openness and transparency, and to promote understanding of how recommendations are developed. The comments are published as a record of the comments we received, and are not endorsed by NICE, its officers or advisory Committees.

Please add extra rows as needed

Please return to: CannabisMedUse@nice.org.uk

NICE reserves the right to summarise and edit comments received during consultations, or not to publish them at all, where in the reasonable opinion of NICE, the comments are voluminous, publication would be unlawful or publication would be otherwise inappropriate.